Literature DB >> 17255738

Is HIV-2- induced AIDS different from HIV-1-associated AIDS? Data from a West African clinic.

Euridice Martinez-Steele1, Akum Aveika Awasana, Tumani Corrah, Saihou Sabally, Marianne van der Sande, Assan Jaye, Toyin Togun, Ramu Sarge-Njie, Samuel J McConkey, Hilton Whittle, Maarten F Schim van der Loeff.   

Abstract

BACKGROUND: Although AIDS is less frequent following HIV-2 than HIV-1 infection, it is unclear whether the clinical picture and clinical course of AIDS are similar in the two infections.
OBJECTIVES: To compare the pattern of AIDS-defining events, CD4 cell count at the time of AIDS diagnosis, survival from time of AIDS, and CD4 cell count near time of death in HIV-1 and HIV-2-infected patients.
METHODS: Adult patients with AIDS who attended the clinics of the MRC in The Gambia were enrolled. AIDS was diagnosed according to the expanded World Health Organization case definition for AIDS surveillance (1994).
RESULTS: Three hundred and forty-one AIDS patients with HIV-1 and 87 with HIV-2 infection were enrolled. The most common AIDS-defining events in both infections were the wasting syndrome and pulmonary tuberculosis. The median CD4 cell count at AIDS was 109 cells/microl in HIV-1 and 176 in HIV-2 (P = 0.01) and remained significantly higher in HIV-2 after adjustment for age and sex (P = 0.03). The median time to death was 6.3 months in HIV-1 and 12.6 months in HIV-2-infected patients (P = 0.03). In a multivariable analysis adjusting for age, sex and CD4 cell count, the mortality rates of HIV-1 and HIV-2-infected patients were similar (P = 0.25). The median CD4 cell count near time of death was 62 and 120 cells/microl in HIV-1 and HIV-2-infected patients, respectively (P = 0.02).
CONCLUSIONS: HIV-2 patients have a higher CD4 cell count at the time of AIDS, and a longer survival after AIDS. The mortality after an AIDS diagnosis is more influenced by CD4 cell count than HIV type.

Entities:  

Mesh:

Year:  2007        PMID: 17255738     DOI: 10.1097/QAD.0b013e328011d7ab

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  24 in total

1.  HIV-1 and HIV-2 differentially mature plasmacytoid dendritic cells into IFN-producing cells or APCs.

Authors:  Caroline M Royle; David R Graham; Simone Sharma; Dietmar Fuchs; Adriano Boasso
Journal:  J Immunol       Date:  2014-08-25       Impact factor: 5.422

2.  Comparison of the Antiviral Activity of Bictegravir against HIV-1 and HIV-2 Isolates and Integrase Inhibitor-Resistant HIV-2 Mutants.

Authors:  Robert A Smith; Dana N Raugi; Vincent H Wu; Christopher G Zavala; Jennifer Song; Khardiata Mbaye Diallo; Moussa Seydi; Geoffrey S Gottlieb
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

3.  First-year lymphocyte T CD4+ response to antiretroviral therapy according to the HIV type in the IeDEA West Africa collaboration.

Authors:  Julia Drylewicz; Serge Eholie; Moussa Maiga; Djimon Marcel Zannou; Papa Salif Sow; Didier K Ekouevi; Kevin Peterson; Emmanuel Bissagnene; François Dabis; Rodolphe Thiébaut
Journal:  AIDS       Date:  2010-04-24       Impact factor: 4.177

Review 4.  Update on human immunodeficiency virus (HIV)-2 infection.

Authors:  Omobolaji T Campbell-Yesufu; Rajesh T Gandhi
Journal:  Clin Infect Dis       Date:  2011-03-15       Impact factor: 9.079

5.  Higher homologous and lower cross-reactive Gag-specific T-cell responses in human immunodeficiency virus type 2 (HIV-2) than in HIV-1 infection.

Authors:  Wim Jennes; Makhtar Camara; Tandakha Dièye; Souleymane Mboup; Luc Kestens
Journal:  J Virol       Date:  2008-06-18       Impact factor: 5.103

6.  Effect of complement on HIV-2 plasma antiviral activity is intratype specific and potent.

Authors:  Gülşen Özkaya Şahin; Birgitta Holmgren; Enas Sheik-Khalil; Zacarias da Silva; Jens Nielsen; Salma Nowroozalizadeh; Fredrik Månsson; Hans Norrgren; Peter Aaby; Eva Maria Fenyö; Marianne Jansson
Journal:  J Virol       Date:  2012-10-17       Impact factor: 5.103

7.  HIV 2: A Benign Onlooker or A Subtle Threat?

Authors:  Ekadashi Rajni Sabharwal; Shweta Gupta; Gaurav Dalela
Journal:  J Clin Diagn Res       Date:  2014-05-15

Review 8.  Mortality and survival patterns of people living with HIV-2.

Authors:  Boris Tchounga; Didier K Ekouevi; Eric Balestre; François Dabis
Journal:  Curr Opin HIV AIDS       Date:  2016-09       Impact factor: 4.283

9.  Comparison of viro-immunological marker changes between HIV-1 and HIV-2-infected patients in France.

Authors:  Julia Drylewicz; Sophie Matheron; Estibaliz Lazaro; Florence Damond; Fabrice Bonnet; François Simon; François Dabis; Françoise Brun-Vezinet; Geneviève Chêne; Rodolphe Thiébaut
Journal:  AIDS       Date:  2008-02-19       Impact factor: 4.177

10.  In Vitro Antiviral Activity of Cabotegravir against HIV-2.

Authors:  Robert A Smith; Vincent H Wu; Christopher G Zavala; Dana N Raugi; Selly Ba; Moussa Seydi; Geoffrey S Gottlieb
Journal:  Antimicrob Agents Chemother       Date:  2018-09-24       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.